Skip to main content

Table 2 Model variables: direct medical costs

From: Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer

  Sensitivity analysis
Base value ($) Minimum ($) Maximum ($) Distribution ($)
TAS-102 1833.66516 1375.24887 2292.08145 Gamma
Bevacizumab 767.945701 575.959276 959.932127 Gamma
Outpatient chemotherapy     
IV drip fee 65.6108597 49.2081448 82.0135747 Gamma
Administration fee for chemotherapy 36.199095 27.1493213 45.2488688 Gamma
Outpatient service fee 6.60633484 4.95475113 8.25791855 Gamma
Prescription fee 3.80090498 2.85067873 4.75113122 Gamma
Administration fee for chemotherapy(monotherapy) 10.4072398 7.80542986 13.0090498 Gamma
Administration fee for chemotherapy (combination) 220.633484 165.475113 275.791855 Gamma
Costs for management of complication (monotherapy) 28.7519014 21.5639261 35.9398768 Gamma
Costs for management of complication (combination) 72.0921038 54.0690778 90.1151297 Gamma